| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.01 per share |
| (b) | Name of Issuer:
SVRN, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
Pendelis 26, Palaio Faliro, Athens,
GREECE
, 175 64. |
Item 1 Comment:
This Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock"), of SVRN, Inc. (formerly known as OceanPal Inc.), a corporation organized under the laws of the Republic of the Marshall Islands (the "Issuer"). The Issuer changed its name from OceanPal Inc. to SVRN, Inc. effective upon the filing of an amendment to its Amended and Restated Articles of Incorporation with the Registrar of Corporations of the Republic of the Marshall Islands on August 27, 2026. The Common Stock is listed on the Nasdaq Capital Market under the symbol "SVRN." The principal executive offices of the Issuer are located at Pendelis 26, 175 64 Palaio Faliro, Athens, Greece. |
| Item 2. | Identity and Background |
|
| (a) | This Schedule 13D is being filed jointly by (i) Proximity Labs, an exempted company limited by shares incorporated under the laws of the Cayman Islands ("Proximity Labs"); (ii) Proximity Foundation, an exempted foundation company limited by guarantee incorporated under the laws of the Cayman Islands ("Proximity Foundation"); (iii) Kendall Cole; and (iv) Marc Piano (each, a "Reporting Person" and, collectively, the "Reporting Persons"). The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date of this Schedule 13D, a copy of which is filed as Exhibit 99.1 and incorporated herein by reference, pursuant to which the Reporting Persons have agreed to file this Schedule 13D jointly in accordance with Rule 13d-1(k)(1) under the Act.
Proximity Labs is the record holder of the securities reported in this Schedule 13D. Proximity Foundation is the sole member of Proximity Labs, holding the one issued ordinary share of Proximity Labs, and is the sole director of Proximity Labs. Proximity Foundation is a foundation company limited by guarantee and does not have shareholders. Proximity Foundation has no members, beneficiaries or ultimate beneficial owners, and its business and affairs are managed solely by its two directors, Kendall Cole and Marc Piano. Kendall Cole and Marc Piano, as the two directors of Proximity Foundation, act on behalf of Proximity Labs and may be deemed to share voting and investment control over the securities held by Proximity Labs. The name, business address, present principal occupation or employment and citizenship of each director, executive officer and controlling person of Proximity Labs and Proximity Foundation are set forth on Schedule A hereto and incorporated herein by reference. |
| (b) | The principal business address of each of Proximity Labs and Proximity Foundation is c/o International Corporation Services Ltd., Harbour Place, 2nd Floor, 103 South Church Street, PO Box 472, George Town, Grand Cayman KY1-1106, Cayman Islands. The business address of each of Kendall Cole and Marc Piano is c/o International Corporation Services Ltd., Harbour Place, 2nd Floor, 103 South Church Street, PO Box 472, George Town, Grand Cayman KY1-1106, Cayman Islands. |
| (c) | The principal business of Proximity Labs is the research and development of open-source software in the NEAR Protocol ecosystem. Proximity Foundation is a holding company whose principal objects are to support projects focused on blockchain composability and cross-chain stacks, including the NEAR Protocol. Each of Kendall Cole and Marc Piano serve as a director of Proximity Foundation, the principal business and address of which are set forth in this Item 2. |
| (d) | During the last five years, none of the Reporting Persons and, to the knowledge of the Reporting Persons, none of the persons listed on Schedule A hereto has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). |
| (e) | During the last five years, none of the Reporting Persons and, to the knowledge of the Reporting Persons, none of the persons listed on Schedule A hereto has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
| (f) | Proximity Labs is organized under the laws of the Cayman Islands. Proximity Foundation is organized under the laws of the Cayman Islands. Kendall Cole is a citizen of the United States of America. Marc Piano is a citizen of the United Kingdom. |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | Common Stock. Pursuant to a Subscription Agreement, dated October 27, 2025, between the Issuer and Proximity Labs (the "Subscription Agreement"), Proximity Labs subscribed for and, on October 28, 2025, acquired 2,352,941 shares of Common Stock (117,647 shares on a post-Reverse Split basis) at a purchase price of $1.275 per share, for an aggregate purchase price of $2,999,999.78. In accordance with the Subscription Agreement, the purchase price was paid in native tokens of the NEAR Protocol ("NEAR Tokens") by transfer of 1,310,043.67 NEAR Tokens to a custodial wallet in the name of SovereignAI Services LLC, a subsidiary of the Issuer. The number of NEAR Tokens delivered was determined by dividing the aggregate purchase price by $2.29, the time-weighted average price of NEAR Tokens on Binance Spot over the 24-hour period specified in the Subscription Agreement. The NEAR Tokens used to fund the purchase were drawn from Proximity Labs' existing holdings of NEAR Tokens. Series B Preferred Stock. Pursuant to a Stock Purchase Agreement, dated October 28, 2025, between Diana Shipping Inc. ("Diana Shipping"), as seller, and Proximity Labs, as buyer (the "SPA"), Proximity Labs acquired 241,362 shares of Series B Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B Preferred Stock") for an aggregate cash purchase price of $2,413.62. The transfer was recorded by the Issuer's transfer agent, Computershare, with a transaction date of November 11, 2025. The purchase price was funded from the working capital of Proximity Labs. No borrowed funds were used to acquire any of the securities reported in this Schedule 13D. The description of the Subscription Agreement in this Schedule 13D is qualified in its entirety by reference to the text of the Subscription Agreement, which is filed as Exhibit 99.2 and incorporated herein by reference. |
| Item 4. | Purpose of Transaction |
| | The Reporting Persons acquired the securities reported in this Schedule 13D in connection with the private placement transactions entered into by the Issuer on October 27, 2025 and closed on October 28, 2025 (collectively, the "PIPE Transaction"), in which the Issuer issued shares of Common Stock and pre-funded warrants to purchase Common Stock to investors for cash and NEAR Tokens. The Issuer disclosed that it intended to use the proceeds of the PIPE Transaction principally to acquire NEAR Tokens and establish NEAR treasury operations. The Reporting Persons acquired the Common Stock as an investment in the Issuer in connection with its adoption of a NEAR-centric digital asset treasury strategy.
Concurrently with the PIPE Transaction, Proximity Labs acquired 241,362 of the 500,000 then-outstanding shares of Series B Preferred Stock from Diana Shipping. Each share of Series B Preferred Stock entitles its holder to 2,000 votes on all matters submitted to a vote of the Issuer's stockholders, voting together with the Common Stock as a single class, subject to the voting limitations described in Item 5. Because the Series B Preferred Stock carries enhanced voting rights, the Reporting Persons may be deemed to have acquired and to hold securities of the Issuer with the purpose or effect of influencing control of the Issuer. Accordingly, the Reporting Persons do not hold their securities of the Issuer solely for passive investment purposes and are reporting their beneficial ownership on Schedule 13D.
As disclosed by the Issuer in its Report on Form 6-K furnished to the Securities and Exchange Commission (the "SEC") on October 28, 2025, in connection with the PIPE Transaction: (i) the Issuer's board of directors amended the Statement of Designation governing the Series B Preferred Stock to limit the voting power that any individual holder, together with its affiliates and related parties, may exercise by virtue of the Series B Preferred Stock to 9.99% of the total voting power of the Issuer's outstanding voting securities; (ii) the holders of the Issuer's Series B Preferred Stock and Series E Preferred Stock agreed to sell all of such shares to certain purchasers in the PIPE Transaction and incoming members of management; (iii) the Issuer amended and restated its stockholders rights agreement; and (iv) effective October 28, 2025, Semiramis Paliou resigned as Chairperson and a member of the Issuer's board of directors, and Salvatore Ternullo was appointed to fill the resulting vacancy as a Class I Director, Chairperson and Co-Chief Executive Officer of the Issuer. The Issuer subsequently disclosed that, effective October 7, 2026, Mr. Ternullo became the Issuer's sole Chief Executive Officer and continues to serve as Chairman of its board of directors. None of the Reporting Persons nominated, designated or proposed Mr. Ternullo for appointment to any position with the Issuer, and none of the Reporting Persons has any agreement or understanding with Mr. Ternullo with respect to the Issuer or its securities.
Proximity Labs agreed, pursuant to a lock-up letter agreement with the Issuer dated October 27, 2025 (the "Lock-Up Agreement"), not to sell, transfer, pledge, hedge or otherwise dispose of its Common Stock and certain related securities, subject to customary exceptions, until the effectiveness of the resale registration statement required by the Subscription Agreement and, with respect to 50% of such securities, for an additional 30 days thereafter, subject to automatic termination 180 days after the closing date of the PIPE Transaction or when such securities could be sold without restriction under Rule 144. As of the date of this Schedule 13D, the restrictions under the Lock-Up Agreement have terminated in accordance with their terms. The Issuer filed a registration statement on Form F-3 with the SEC on November 26, 2025, registering, among other securities, the resale of the shares of Common Stock held by Proximity Labs.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including the Issuer's financial position and strategic direction, the price of the Common Stock and of NEAR Tokens, conditions in the securities and digital asset markets, and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate. Such actions may include purchasing additional securities of the Issuer, selling some or all of their securities of the Issuer (including pursuant to the Issuer's resale registration statement or Rule 144), voting their shares of Common Stock and Series B Preferred Stock on matters submitted to the Issuer's stockholders, and engaging in communications with the Issuer's management, board of directors and other stockholders regarding the Issuer's business, strategy and governance.
Except as set forth in this Schedule 13D, none of the Reporting Persons has any present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate other plans or proposals, and to take any action with respect to their investment in the Issuer, including any or all of the actions set forth in this Item 4, at any time and from time to time. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | As of the date of this Schedule 13D, each Reporting Person may be deemed to beneficially own 117,647 shares of Common Stock (2,352,941 shares on a pre-Reverse Split basis), all of which are held of record by Proximity Labs, representing approximately 6.3% of the outstanding Common Stock. This percentage is calculated on the basis of 1,875,816 shares of Common Stock outstanding as of May 8, 2026, as reported by the Issuer in the proxy statement furnished as Exhibit 99.2 to its Report on Form 6-K furnished on May 13, 2026. That figure is consistent with the Issuer's Articles of Amendment effecting the Reverse Split, furnished as Exhibit 3.1 to its Report on Form 6-K furnished on March 30, 2026, which reported that the number of issued shares of Common Stock decreased from 37,517,290 to 1,875,864 shares, as adjusted for the cancellation of fractional shares.
As of October 28, 2025, the date of the event requiring the filing of this Schedule 13D, the shares reported in this Schedule 13D represented approximately 7.6% of the 31,121,477 shares of Common Stock outstanding immediately following the closing of the PIPE Transaction (approximately 1,556,074 shares on a post-Reverse Split basis). That figure is derived from (i) the 6,696,039 shares of Common Stock outstanding as of October 27, 2025, as represented by the Issuer in the Subscription Agreement, plus (ii) the 20,896,027 shares of Common Stock issued in the PIPE Transaction and the 3,529,411 shares of Common Stock issued to certain insiders of the Issuer in connection with the PIPE Transaction, each as disclosed in the Issuer's Report on Form 6-K furnished on October 28, 2025.
The Issuer's registration statement on Form F-3 filed on November 26, 2025 reported 109,510,789 shares of Common Stock outstanding as of November 25, 2025, assuming the exercise in full of pre-funded warrants to purchase 75,210,318 shares of Common Stock issued in the PIPE Transaction, without regard to the beneficial ownership limitations on their exercise. Excluding those warrant shares, the Form F-3 indicates 34,300,471 shares of Common Stock outstanding as of November 25, 2025 (approximately 1,715,024 shares on a post-Reverse Split basis), on which basis the shares reported in this Schedule 13D would represent approximately 6.9% of the outstanding Common Stock. The percentage of 2.15% attributed to Proximity Labs in the Form F-3 reflects the Issuer's fully diluted presentation and does not reflect a calculation under Rule 13d-3 under the Act. Proximity Labs does not hold any pre-funded warrants or other rights to acquire Common Stock. In accordance with Rule 13d-3(d)(1)(i) under the Act, shares of Common Stock issuable upon exercise of pre-funded warrants held by other persons are not deemed outstanding for purposes of computing the percentage of Common Stock beneficially owned by the Reporting Persons.
The actual percentage may differ to the extent the Issuer has issued or repurchased shares of Common Stock after the dates of the information described above, including upon exercise of pre-funded warrants or pursuant to its at-the-market offering program.
Proximity Labs also holds 241,362 shares of Series B Preferred Stock, representing approximately 48.3% of the 500,000 outstanding shares of Series B Preferred Stock. The Series B Preferred Stock is not registered under Section 12 of the Act, is not convertible into Common Stock at the option of the holder, and is not included in the number of shares of Common Stock reported as beneficially owned in this Schedule 13D. Under the Issuer's Amended and Restated Statement of Designation of the Series B Preferred Stock, each share entitles its holder to 2,000 votes, subject to limitations under which (i) the aggregate votes of all holders by virtue of the Series B Preferred Stock may not exceed 34.0% of the total votes eligible to be cast on any matter, allocated among holders in proportion to their holdings of Series B Preferred Stock, (ii) a holder's aggregate voting power may not exceed 49.0% of the total votes eligible to be cast, and (iii) the total votes that any one holder may cast by virtue of the Series B Preferred Stock, together with its Common Stock and other voting securities of the Issuer, may not exceed 9.99% of the total votes eligible to be cast on any matter. For these purposes, a holder includes each beneficial owner of the Series B Preferred Stock under Rule 13d-3 under the Act and its affiliates. As a result of these limitations, the Reporting Persons estimate that they may exercise up to 9.99% of the total voting power of the Issuer on matters submitted to the Issuer's stockholders. The number of shares of Series B Preferred Stock was not adjusted as a result of the Reverse Split. |
| (b) | Each of the Reporting Persons may be deemed to share the power to vote or direct the vote, and to dispose or direct the disposition of, the 117,647 shares of Common Stock and the 241,362 shares of Series B Preferred Stock held by Proximity Labs. None of the Reporting Persons has sole power to vote or dispose of any such securities. Each of Kendall Cole and Marc Piano may be deemed to share such power solely in his capacity as one of the two directors of Proximity Foundation, has no pecuniary interest in such securities and disclaims beneficial ownership of such securities. Proximity Foundation disclaims beneficial ownership of the securities reported in this Schedule 13D except to the extent of its pecuniary interest therein. The filing of this Schedule 13D shall not be construed as an admission that any of Proximity Foundation, Kendall Cole or Marc Piano is the beneficial owner of such securities for purposes of Section 13(d) of the Act or for any other purpose. |
| (c) | None of the Reporting Persons has effected any transaction in the Common Stock or the Series B Preferred Stock during the past 60 days. |
| (d) | No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported in this Schedule 13D. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | Subscription Agreement. Under the Subscription Agreement, Proximity Labs agreed to purchase 2,352,941 shares of Common Stock (on a pre-Reverse Split basis) at $1.275 per share, payable in NEAR Tokens as described in Item 3. Proximity Labs did not subscribe for pre-funded warrants and did not elect to be subject to the optional beneficial ownership limitation in Section 2.f of the Subscription Agreement. The Issuer agreed to file a registration statement registering the resale of the shares of Common Stock acquired in the PIPE Transaction and to use commercially reasonable efforts to cause it to become effective. The Subscription Agreement contains customary representations, warranties, covenants and indemnification provisions. Section 3.z of the Subscription Agreement includes a representation by the Issuer that it has not entered into any side letter or similar agreement with any investor in connection with the PIPE Transaction, other than, among other things, certain agreements with affiliates of NEAR Foundation, Proximity Labs and Frontier Growth Holdings Limited and their respective affiliates. The Reporting Persons understand this reference to include the stock purchase agreements under which each of Proximity Labs, NEAR Foundation and Frontier Growth Holdings Limited separately acquired shares of Series B Preferred Stock from Diana Shipping.
Stock Purchase Agreement. Under the SPA, Diana Shipping sold, and Proximity Labs purchased, 241,362 shares of Series B Preferred Stock for an aggregate cash purchase price of $2,413.62. The SPA contains customary representations and warranties of the parties, including a representation by Proximity Labs that it acquired the shares for investment purposes, and reciprocal indemnification obligations limited to the purchase price. The SPA is governed by New York law. In separate transactions with Diana Shipping, NEAR Foundation acquired 71,338 shares, and Frontier Growth Holdings Limited acquired 187,300 shares, of Series B Preferred Stock.
Lock-Up Agreement. The terms of the Lock-Up Agreement are described in Item 4 and incorporated herein by reference. As of the date of this Schedule 13D, the restrictions under the Lock-Up Agreement have terminated.
Statement of Designation of Series B Preferred Stock. The voting rights and limitations of the Series B Preferred Stock are described in Item 5(a) and incorporated herein by reference. In addition, under the Amended and Restated Statement of Designation, the Series B Preferred Stock has no dividend, distribution or liquidation rights, is not redeemable, and may not be transferred by a holder except to an affiliate or successor of such holder without the prior written consent of the Issuer. In any consolidation, merger or similar transaction in which the Common Stock is exchanged for or changed into other securities, cash or property, each share of Series B Preferred Stock will be exchanged or changed into the same amount of consideration as each share of Common Stock. The number of outstanding shares of Series B Preferred Stock is not adjusted for any stock dividend, subdivision or combination of the Common Stock.
Relationship with Other Investors. Neither Proximity Labs nor any other Reporting Person controls, is controlled by or is under common control with NEAR Foundation or Frontier Growth Holdings Limited, and neither Proximity Labs nor any other Reporting Person takes direction from, or shares investment or voting decisions with, NEAR Foundation or Frontier Growth Holdings Limited with respect to securities of the Issuer. None of the Reporting Persons is party to any agreement, arrangement or understanding with NEAR Foundation, Frontier Growth Holdings Limited or any other investor in the PIPE Transaction for the purpose of acquiring, holding, voting or disposing of securities of the Issuer. The Reporting Persons do not believe that they constitute a "group" within the meaning of Section 13(d)(3) of the Act with any such person and expressly disclaim beneficial ownership of any securities of the Issuer held by any such person. The Reporting Persons have not included in this Schedule 13D any securities of the Issuer held by any such person.
Joint Filing Agreement. The Reporting Persons have entered into the Joint Filing Agreement described in Item 2.
Except as described in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons, or between any Reporting Person and any other person, with respect to any securities of the Issuer. The descriptions of the agreements in this Item 6 are qualified in their entirety by reference to the full text of such agreements, which are filed or incorporated by reference as exhibits to this Schedule 13D. |
| Item 7. | Material to be Filed as Exhibits. |
| | 99.1- Joint Filing Agreement, dated as of November 18, 2026, among the Reporting Persons (filed herewith; attached as Part III of this document). 99.2-Subscription Agreement, dated October 27, 2025, between OceanPal Inc. and Proximity Labs (incorporated by reference to Exhibit 10.2 to the Issuer's Report on Form 6-K furnished on October 28, 2025. 99.3-Amended and Restated Statement of Designation of Rights, Preferences and Privileges of Series B Preferred Stock of OceanPal Inc. (incorporated by reference to Exhibit 4.2 to the Issuer's Report on Form 6-K furnished on October 28, 2025). |